Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1AQVE)

• Drug Name: DPI-201-106 Drug Info
• Synonyms: 4-{3-[4-(Diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; Dpi 201-106; 97730-95-5; SDZ-201106; CHEMBL314639; SDZ-201 106 (+/-); 4-{3-[4-(diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; (+-)-4-(3-(4-(Diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile; 1H-Indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy-, (+-)-; 4(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile; CBiol_001886; DPI-201106; 4-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 5190
  ChEBI ID: CHEBI:110175
  CAS Number: CAS 97730-95-5
  TTD Drug ID: DM1AQVE

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[4]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[5]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[6]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[7]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[8]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[9]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[10]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[11]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[12]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[13]

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[14]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[15]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[16]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[17]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[18]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[19]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[20]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[21]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[22]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Inhibitor	[2]
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Modulator	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000134)
• [2] Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5.
• [3] Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17-24.
• [4] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [5] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [6] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [7] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [8] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [9] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [10] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [13] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [14] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [15] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [16] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [17] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [18] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [19] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [20] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [23] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.